|
US5703058A
(en)
|
1995-01-27 |
1997-12-30 |
Emory University |
Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
|
|
IL138037A0
(en)
*
|
1998-02-25 |
2001-10-31 |
Univ Emory |
2'-fluoronucleosides
|
|
HUP0301112A3
(en)
|
2000-02-18 |
2005-04-28 |
Shire Biochem Inc Laval |
Method for the treatment or prevention of flavivirus infections using nucleoside analogues
|
|
US7094770B2
(en)
|
2000-04-13 |
2006-08-22 |
Pharmasset, Ltd. |
3′-or 2′-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections
|
|
MY164523A
(en)
*
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
|
CZ301182B6
(cs)
*
|
2000-05-26 |
2009-12-02 |
Idenix (Cayman) Limited |
Použití nukleosidových derivátu pro výrobu farmaceutických prostredku pro lécení infekcí vyvolaných flaviviry a pestiviry
|
|
FR2810319A1
(fr)
*
|
2000-06-15 |
2001-12-21 |
Ppg Sipsy |
Composes alpha-phenylsulfinyl-alpha-halogeno-butyrolactone et halogeno-2-buten-2-olide-4 utiles pour la preparation de composes halogeno-2-oxymethyl-4-furanone (4h)
|
|
US20030008841A1
(en)
*
|
2000-08-30 |
2003-01-09 |
Rene Devos |
Anti-HCV nucleoside derivatives
|
|
KR101005299B1
(ko)
*
|
2000-10-18 |
2011-01-04 |
파마셋 인코포레이티드 |
바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
|
|
US8481712B2
(en)
|
2001-01-22 |
2013-07-09 |
Merck Sharp & Dohme Corp. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
|
US7105499B2
(en)
*
|
2001-01-22 |
2006-09-12 |
Merck & Co., Inc. |
Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
|
|
HUP0400726A3
(en)
*
|
2001-01-22 |
2007-05-29 |
Merck & Co Inc |
Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
|
|
US6900315B2
(en)
|
2001-02-06 |
2005-05-31 |
Yale University |
2-amino-9H-purin-9-yl compounds and methods for inhibiting/treating HIV infections and AIDS related symptoms
|
|
RU2003129164A
(ru)
|
2001-03-01 |
2005-03-20 |
Фармассет Лтд. (Bb) |
Способ синтеза 2`,3`-дидезокси-2`,3`-дидегидронуклеозидов
|
|
WO2002069903A2
(en)
*
|
2001-03-06 |
2002-09-12 |
Biocryst Pharmaceuticals, Inc. |
Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
|
|
GB0112617D0
(en)
*
|
2001-05-23 |
2001-07-18 |
Hoffmann La Roche |
Antiviral nucleoside derivatives
|
|
GB0114286D0
(en)
|
2001-06-12 |
2001-08-01 |
Hoffmann La Roche |
Nucleoside Derivatives
|
|
JP2005503358A
(ja)
|
2001-06-22 |
2005-02-03 |
フアーマセツト・リミテツド |
β−２’−または３’−ハロヌクレオシド
|
|
WO2003026589A2
(en)
*
|
2001-09-28 |
2003-04-03 |
Idenix (Cayman) Limited |
Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides
|
|
US7049303B2
(en)
*
|
2001-11-07 |
2006-05-23 |
Medical Research Council |
Inhibition of viruses
|
|
WO2003063771A2
(en)
*
|
2001-12-14 |
2003-08-07 |
Pharmasset Ltd. |
N4-acylcytosine nucleosides for treatment of viral iinfections
|
|
US20040002476A1
(en)
*
|
2002-02-14 |
2004-01-01 |
Stuyver Lieven J. |
Modified fluorinated nucleoside analogues
|
|
US7608600B2
(en)
*
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
|
CN101172993A
(zh)
*
|
2002-06-28 |
2008-05-07 |
埃迪尼克斯(开曼)有限公司 |
用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
|
|
TW200500375A
(en)
|
2002-06-28 |
2005-01-01 |
Idenix Cayman Ltd |
Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
|
|
WO2004002422A2
(en)
*
|
2002-06-28 |
2004-01-08 |
Idenix (Cayman) Limited |
2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
|
|
US20040067877A1
(en)
|
2002-08-01 |
2004-04-08 |
Schinazi Raymond F. |
2', 3'-Dideoxynucleoside analogues for the treatment or prevention of Flaviviridae infections
|
|
IL166640A0
(en)
|
2002-08-01 |
2006-01-15 |
Pharmasset Ltd |
Compounds with the bicyclo Ä4.2.1Ü nonane system for the treatment of flaviviridae infections
|
|
US6884880B2
(en)
*
|
2002-08-21 |
2005-04-26 |
Ash Stevens, Inc. |
Process for the preparation of 9-β-anomeric nucleoside analogs
|
|
US7902203B2
(en)
*
|
2002-11-01 |
2011-03-08 |
Abbott Laboratories, Inc. |
Anti-infective agents
|
|
ES2624353T3
(es)
*
|
2002-11-15 |
2017-07-13 |
Idenix Pharmaceuticals Llc |
2'-Metil nucleósidos en combinación con interferón y mutación de Flaviviridae
|
|
RU2005121904A
(ru)
*
|
2002-12-12 |
2006-01-20 |
Айденикс (Кайман) Лимитед (Ky) |
Способ получения 2`-разветвленных нуклеозидов
|
|
JP2006514038A
(ja)
*
|
2002-12-23 |
2006-04-27 |
イデニクス（ケイマン）リミテツド |
３’−ヌクレオシドプロドラッグの生産方法
|
|
US20050049204A1
(en)
*
|
2003-03-28 |
2005-03-03 |
Otto Michael J. |
Compounds for the treatment of flaviviridae infections
|
|
CN1812995A
(zh)
*
|
2003-04-28 |
2006-08-02 |
艾登尼科斯（开曼）有限公司 |
工业化规模的核苷合成
|
|
EP4032897B1
(en)
|
2003-05-30 |
2025-01-29 |
Gilead Pharmasset LLC |
Modified fluorinated nucleoside analogues
|
|
MXPA06000162A
(es)
|
2003-06-30 |
2006-03-21 |
Idenix Cayman Ltd |
Sintesis de ?-l-2-desoxinucleosidos.
|
|
ATE478886T1
(de)
*
|
2003-07-25 |
2010-09-15 |
Idenix Pharmaceuticals Inc |
Purin nucleoside für die behandlung von durch flavividrae verursachten krankheiten, einschliesslich hepatitis c
|
|
WO2005018330A1
(en)
*
|
2003-08-18 |
2005-03-03 |
Pharmasset, Inc. |
Dosing regimen for flaviviridae therapy
|
|
CA2537114C
(en)
|
2003-08-27 |
2012-10-02 |
Biota, Inc. |
Tricyclic nucleosides or nucleotides as therapeutic agents
|
|
WO2005026186A1
(de)
*
|
2003-09-12 |
2005-03-24 |
Max-Delbrück-Centrum für Molekulare Medizin |
Β-l-nucleoside und ihre verwendung als pharmazeutische mittel zur behandlung viraler erkrankungen
|
|
GB0500020D0
(en)
|
2005-01-04 |
2005-02-09 |
Novartis Ag |
Organic compounds
|
|
US20050182252A1
(en)
|
2004-02-13 |
2005-08-18 |
Reddy K. R. |
Novel 2'-C-methyl nucleoside derivatives
|
|
KR100839394B1
(ko)
*
|
2004-06-09 |
2008-06-20 |
에프. 호프만-라 로슈 아게 |
피라졸로 피리미딘
|
|
US7405220B2
(en)
*
|
2004-06-09 |
2008-07-29 |
Hoffmann-La Roche Inc. |
Pyrazolopyrimidines
|
|
JP5055564B2
(ja)
|
2004-06-15 |
2012-10-24 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Ｒｎａ依存性ｒｎａウイルスポリメラーゼの阻害剤としてのｃ−プリンヌクレオシド類似体
|
|
US20060040944A1
(en)
*
|
2004-06-23 |
2006-02-23 |
Gilles Gosselin |
5-Aza-7-deazapurine derivatives for treating Flaviviridae
|
|
EP1773355B1
(en)
|
2004-06-24 |
2014-06-25 |
Merck Sharp & Dohme Corp. |
Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
|
|
CN101023094B
(zh)
*
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
|
ES2327252T3
(es)
*
|
2004-08-23 |
2009-10-27 |
F. Hoffmann-La Roche Ag |
4'-azido nucleosidos antivirales.
|
|
WO2006031725A2
(en)
|
2004-09-14 |
2006-03-23 |
Pharmasset, Inc. |
Preparation of 2'fluoro-2'- alkyl- substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
|
|
WO2006093801A1
(en)
*
|
2005-02-25 |
2006-09-08 |
Abbott Laboratories |
Thiadiazine derivatives useful as anti-infective agents
|
|
US7524831B2
(en)
|
2005-03-02 |
2009-04-28 |
Schering Corporation |
Treatments for Flaviviridae virus infection
|
|
AU2006222563A1
(en)
|
2005-03-08 |
2006-09-14 |
Biota Scientific Management Pty Ltd. |
Bicyclic nucleosides and nucleotides as therapeutic agents
|
|
JP4516863B2
(ja)
*
|
2005-03-11 |
2010-08-04 |
株式会社ケンウッド |
音声合成装置、音声合成方法及びプログラム
|
|
AU2006242475B2
(en)
|
2005-05-02 |
2011-07-07 |
Merck Sharp & Dohme Corp. |
HCV NS3 protease inhibitors
|
|
US7470664B2
(en)
|
2005-07-20 |
2008-12-30 |
Merck & Co., Inc. |
HCV NS3 protease inhibitors
|
|
JP4705984B2
(ja)
|
2005-08-01 |
2011-06-22 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Ｈｃｖｎｓ３プロテアーゼ阻害剤としての大環状ペプチド
|
|
US7705009B2
(en)
*
|
2005-11-22 |
2010-04-27 |
Hoffman-La Roche Inc. |
4-aminopyrimidine-5-thione derivatives
|
|
CA2632626C
(en)
|
2005-12-09 |
2011-10-11 |
F. Hoffmann-La Roche Ag |
Ester prodrugs of 2'-fluoro-2'-alkyl-2'-deoxycytidines and their use in the treatment of hcv infection
|
|
EP2345652A1
(en)
|
2005-12-21 |
2011-07-20 |
Abbott Laboratories |
Antiviral compounds
|
|
WO2007081517A2
(en)
|
2005-12-21 |
2007-07-19 |
Abbott Laboratories |
Anti-viral compounds
|
|
EP1979349B1
(en)
|
2005-12-21 |
2010-07-28 |
Abbott Laboratories |
Anti-viral compounds
|
|
RU2441869C2
(ru)
*
|
2005-12-21 |
2012-02-10 |
Эбботт Лэборетриз |
Противовирусные соединения
|
|
JP5254033B2
(ja)
*
|
2005-12-23 |
2013-08-07 |
イデニク プハルマセウティカルス，インコーポレイテッド |
分岐型ヌクレオシドを調製するための合成中間体の製造方法
|
|
KR101237312B1
(ko)
*
|
2006-02-10 |
2013-03-04 |
삼진제약주식회사 |
피리미딘다이온 유도체를 포함하는 ｃ형 간염의 예방 및치료용 약학 조성물
|
|
US8895531B2
(en)
*
|
2006-03-23 |
2014-11-25 |
Rfs Pharma Llc |
2′-fluoronucleoside phosphonates as antiviral agents
|
|
US9644039B2
(en)
*
|
2006-03-24 |
2017-05-09 |
The Regents Of The University Of California |
Acid-degradable and bioerodible modified polyhydroxylated materials
|
|
WO2010005847A1
(en)
*
|
2008-07-08 |
2010-01-14 |
The Regents Of The University Of California |
Acid-degradable and bioerodible modified polyhydroxylated materials
|
|
WO2007133865A2
(en)
|
2006-04-11 |
2007-11-22 |
Novartis Ag |
Hcv/hiv inhibitors an their uses
|
|
GB0609492D0
(en)
|
2006-05-15 |
2006-06-21 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
|
GB0612423D0
(en)
|
2006-06-23 |
2006-08-02 |
Angeletti P Ist Richerche Bio |
Therapeutic agents
|
|
US7662958B2
(en)
*
|
2006-07-19 |
2010-02-16 |
Rolf Wagner |
Anti-infective agents
|
|
US20090298708A1
(en)
*
|
2006-08-23 |
2009-12-03 |
Masad Damha J |
2'-deoxy-2'-fluoro-beta-d-arabinonucleoside 5'-triphosphates and their use in enzymatic nucleic acid synthesis
|
|
EP2084175B1
(en)
*
|
2006-10-10 |
2010-12-29 |
Medivir AB |
Hcv nucleoside inhibitor
|
|
WO2008045419A1
(en)
|
2006-10-10 |
2008-04-17 |
Pharmasset, Inc. |
Preparation of nucleosides ribofuranosyl pyrimidines
|
|
EP2079480B1
(en)
|
2006-10-24 |
2013-06-05 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
|
AU2007309544B2
(en)
|
2006-10-24 |
2012-05-31 |
Msd Italia S.R.L. |
HCV NS3 protease inhibitors
|
|
AU2007309546A1
(en)
|
2006-10-24 |
2008-05-02 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
HCV NS3 protease inhibitors
|
|
AU2007318165B2
(en)
|
2006-10-27 |
2011-11-17 |
Msd Italia S.R.L. |
HCV NS3 protease inhibitors
|
|
EP2083844B1
(en)
|
2006-10-27 |
2013-11-27 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
|
GB0625345D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
EP2121707B1
(en)
|
2006-12-20 |
2012-12-05 |
Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. |
Antiviral indoles
|
|
WO2008133753A2
(en)
*
|
2006-12-20 |
2008-11-06 |
Abbott Laboratories |
Anti-viral compounds
|
|
GB0625349D0
(en)
|
2006-12-20 |
2007-01-31 |
Angeletti P Ist Richerche Bio |
Therapeutic compounds
|
|
US7951789B2
(en)
|
2006-12-28 |
2011-05-31 |
Idenix Pharmaceuticals, Inc. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
|
AU2007342367B2
(en)
|
2007-01-05 |
2012-12-06 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
|
|
AU2008219622A1
(en)
|
2007-02-28 |
2008-09-04 |
Conatus Pharmaceuticals, Inc. |
Methods for the treatment of liver diseases using specified matrix metalloproteinase (MMP) inhibitors
|
|
EA017183B1
(ru)
*
|
2007-03-23 |
2012-10-30 |
Саузерн Рисерч Инститьют |
Способ лечения и предупреждения артрита
|
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
|
CN100532388C
(zh)
|
2007-07-16 |
2009-08-26 |
郑州大学 |
2’-氟-4’-取代-核苷类似物、其制备方法及应用
|
|
CN101801982A
(zh)
|
2007-07-17 |
2010-08-11 |
P.安杰莱蒂分子生物学研究所 |
用于治疗丙型肝炎感染的大环吲哚衍生物
|
|
US8927569B2
(en)
|
2007-07-19 |
2015-01-06 |
Merck Sharp & Dohme Corp. |
Macrocyclic compounds as antiviral agents
|
|
WO2009058800A2
(en)
*
|
2007-10-29 |
2009-05-07 |
President And Fellows Of Harvard College |
Synthesis of nucleosides
|
|
TW200946541A
(en)
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
|
EP2271345B1
(en)
|
2008-04-28 |
2015-05-20 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
|
US20090274686A1
(en)
*
|
2008-05-02 |
2009-11-05 |
Yat Sun Or |
Nucleoside phosphonate derivatives
|
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
|
KR20110065440A
(ko)
|
2008-07-02 |
2011-06-15 |
아이데닉스 파마슈티칼스, 인코포레이티드 |
바이러스 감염의 치료를 위한 화합물 및 제약 조성물
|
|
EP2313102A2
(en)
|
2008-07-03 |
2011-04-27 |
Biota Scientific Management |
Bycyclic nucleosides and nucleotides as therapeutic agents
|
|
EP2540349B1
(en)
|
2008-07-22 |
2014-02-12 |
Merck Sharp & Dohme Corp. |
Pharmaceutical compositions comprising a macrocyclic quinoxaline compound which is an hcv ns3 protease inhibitor
|
|
SG172359A1
(en)
|
2008-12-23 |
2011-07-28 |
Pharmasset Inc |
Nucleoside phosphoramidates
|
|
US8551973B2
(en)
|
2008-12-23 |
2013-10-08 |
Gilead Pharmasset Llc |
Nucleoside analogs
|
|
NZ593647A
(en)
|
2008-12-23 |
2013-08-30 |
Gilead Pharmasset Llc |
Synthesis of purine nucleosides
|
|
WO2010082050A1
(en)
|
2009-01-16 |
2010-07-22 |
Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. |
Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
|
|
GB0900914D0
(en)
|
2009-01-20 |
2009-03-04 |
Angeletti P Ist Richerche Bio |
Antiviral agents
|
|
JP5690286B2
(ja)
|
2009-03-04 |
2015-03-25 |
イデニク プハルマセウティカルス，インコーポレイテッド |
ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
|
|
US8512690B2
(en)
|
2009-04-10 |
2013-08-20 |
Novartis Ag |
Derivatised proline containing peptide compounds as protease inhibitors
|
|
US20110182850A1
(en)
|
2009-04-10 |
2011-07-28 |
Trixi Brandl |
Organic compounds and their uses
|
|
WO2010132513A1
(en)
*
|
2009-05-12 |
2010-11-18 |
Southern Research Institute |
2'-fluoro arabino nucleosides and use thereof
|
|
MX2011012155A
(es)
|
2009-05-13 |
2012-02-28 |
Enanta Pharm Inc |
Compuestos macrociclicos como inhibidores del virus de hepatitis c.
|
|
TWI598358B
(zh)
|
2009-05-20 |
2017-09-11 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
|
US9676797B2
(en)
|
2015-09-02 |
2017-06-13 |
Abbvie Inc. |
Anti-viral compounds
|
|
US8828930B2
(en)
|
2009-07-30 |
2014-09-09 |
Merck Sharp & Dohme Corp. |
Hepatitis C virus NS3 protease inhibitors
|
|
EP2459211A1
(en)
|
2009-07-31 |
2012-06-06 |
Medtronic, Inc. |
Continuous subcutaneous administration of interferon- to hepatitis c infected patients
|
|
US9284307B2
(en)
|
2009-08-05 |
2016-03-15 |
Idenix Pharmaceuticals Llc |
Macrocyclic serine protease inhibitors
|
|
RU2012122637A
(ru)
|
2009-11-14 |
2013-12-20 |
Ф.Хоффманн-Ля Рош Аг |
Биомаркеры для прогнозирования быстрого ответа на лечение гепатита с
|
|
US8816074B2
(en)
*
|
2009-11-16 |
2014-08-26 |
University of Georgia Foundation, Inc. |
2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
|
|
US9700560B2
(en)
|
2009-11-16 |
2017-07-11 |
University Of Georgia Research Foundation, Inc. |
2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
|
|
US20110117055A1
(en)
|
2009-11-19 |
2011-05-19 |
Macdonald James E |
Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
|
|
BR112012011393A2
(pt)
|
2009-12-02 |
2017-06-20 |
Hoffmann La Roche |
biomarcadores para a previsão da resposta sustentada ao tratamento de hcv
|
|
CA2784748A1
(en)
|
2009-12-18 |
2011-06-23 |
Idenix Pharmaceuticals, Inc. |
5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
|
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
|
JP2013527145A
(ja)
|
2010-03-31 |
2013-06-27 |
ギリード・ファーマセット・エルエルシー |
リン含有活性化剤の立体選択的合成
|
|
EP2552203B1
(en)
|
2010-04-01 |
2017-03-22 |
Idenix Pharmaceuticals LLC. |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
|
US9284188B2
(en)
|
2010-09-03 |
2016-03-15 |
The Regents Of The University Of California |
Cytosolic delivery of materials with endosome-disrupting colloids
|
|
SG188618A1
(en)
|
2010-09-21 |
2013-04-30 |
Enanta Pharm Inc |
Macrocyclic proline derived hcv serine protease inhibitors
|
|
AU2011311880B2
(en)
|
2010-10-08 |
2014-07-24 |
Novartis Ag |
Vitamin E formulations of sulfamide NS3 inhibitors
|
|
PT3042910T
(pt)
|
2010-11-30 |
2019-04-16 |
Gilead Pharmasset Llc |
2'-espiro-nucleósidos para utilização na terapia da hepatite c
|
|
WO2012080050A1
(en)
|
2010-12-14 |
2012-06-21 |
F. Hoffmann-La Roche Ag |
Solid forms of a phenoxybenzenesulfonyl compound
|
|
US9353100B2
(en)
|
2011-02-10 |
2016-05-31 |
Idenix Pharmaceuticals Llc |
Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
|
|
US20120252721A1
(en)
|
2011-03-31 |
2012-10-04 |
Idenix Pharmaceuticals, Inc. |
Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
|
|
US9243025B2
(en)
|
2011-03-31 |
2016-01-26 |
Idenix Pharmaceuticals, Llc |
Compounds and pharmaceutical compositions for the treatment of viral infections
|
|
WO2012142075A1
(en)
|
2011-04-13 |
2012-10-18 |
Merck Sharp & Dohme Corp. |
2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
|
AU2012242978A1
(en)
|
2011-04-13 |
2013-10-24 |
Merck Sharp & Dohme Corp. |
2'-Cyano Substituted Nucleoside Derivatives and methods of use thereof for the treatment of viral diseases
|
|
BR112013026345A2
(pt)
|
2011-04-13 |
2019-04-24 |
Merck Sharp & Dohe Corp. |
composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
|
|
US9408863B2
(en)
|
2011-07-13 |
2016-08-09 |
Merck Sharp & Dohme Corp. |
5′-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases
|
|
US9416154B2
(en)
|
2011-07-13 |
2016-08-16 |
Merck Sharp & Dohme Corp. |
5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
|
|
CN103906759A
(zh)
|
2011-09-12 |
2014-07-02 |
埃迪尼克斯医药公司 |
用于治疗病毒感染的化合物和药物组合物
|
|
WO2013039920A1
(en)
|
2011-09-12 |
2013-03-21 |
Idenix Pharmaceuticals, Inc. |
Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections
|
|
CA2840242C
(en)
|
2011-09-16 |
2019-03-26 |
Gilead Sciences, Inc. |
Methods for treating hcv
|
|
WO2013056046A1
(en)
|
2011-10-14 |
2013-04-18 |
Idenix Pharmaceuticals, Inc. |
Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections
|
|
WO2013070887A1
(en)
*
|
2011-11-10 |
2013-05-16 |
Inhibitex, Inc. |
Substituted purine nucleosides, phosphoramidate and phosphordiamidate derivatives for treatment of viral infections
|
|
EP2780026B1
(en)
|
2011-11-15 |
2019-10-23 |
Merck Sharp & Dohme Corp. |
Hcv ns3 protease inhibitors
|
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
|
EP2785184B1
(en)
|
2011-11-30 |
2020-06-10 |
Emory University |
Compositions comprising jak inhibitors and haart drugs for use in the prevention or treatment of hiv
|
|
WO2013106344A1
(en)
|
2012-01-12 |
2013-07-18 |
Ligand Pharmaceuticals, Inc. |
2 '-c-methyl nucleosides containing a cyclic phosphate diester of 1, 3-propanediol (2-oxo-[1, 3, 2]-dioxaphosphorinane) at position 5'
|
|
WO2013133927A1
(en)
|
2012-02-13 |
2013-09-12 |
Idenix Pharmaceuticals, Inc. |
Pharmaceutical compositions of 2'-c-methyl-guanosine, 5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl n-(phenylmethyl)phosphoramidate]
|
|
MD20140094A2
(ro)
|
2012-02-14 |
2015-03-31 |
University Of Georgia Research Foundation, Inc. |
Spiro [2.4]heptani pentru tratamentul infecţiilor cauzate de Flaviviridae
|
|
BR112014029115A8
(pt)
|
2012-05-22 |
2018-04-03 |
Idenix Pharmaceuticals Inc |
Composto, composição farmacêutica, e, uso de um composto ou composição
|
|
EP2852605B1
(en)
|
2012-05-22 |
2018-01-31 |
Idenix Pharmaceuticals LLC |
3',5'-cyclic phosphate prodrugs for hcv infection
|
|
EP2852604B1
(en)
|
2012-05-22 |
2017-04-12 |
Idenix Pharmaceuticals LLC |
3',5'-cyclic phosphoramidate prodrugs for hcv infection
|
|
MX2014014323A
(es)
|
2012-05-25 |
2015-02-12 |
Janssen R & D Ireland |
Nucleosidos de espirooxetano de uracilo.
|
|
WO2014052638A1
(en)
|
2012-09-27 |
2014-04-03 |
Idenix Pharmaceuticals, Inc. |
Esters and malonates of sate prodrugs
|
|
CN104603146B
(zh)
|
2012-09-29 |
2018-01-02 |
诺华股份有限公司 |
环肽类化合物及其作为药物的用途
|
|
CN104936970A
(zh)
|
2012-10-08 |
2015-09-23 |
埃迪尼克斯医药公司 |
用于hcv感染的2′-氯核苷类似物
|
|
WO2014063019A1
(en)
|
2012-10-19 |
2014-04-24 |
Idenix Pharmaceuticals, Inc. |
Dinucleotide compounds for hcv infection
|
|
US10723754B2
(en)
|
2012-10-22 |
2020-07-28 |
Idenix Pharmaceuticals Llc |
2′,4′-bridged nucleosides for HCV infection
|
|
US20140140952A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Sp-Nucleoside Analog
|
|
US20140140951A1
(en)
|
2012-11-14 |
2014-05-22 |
Idenix Pharmaceuticals, Inc. |
D-Alanine Ester of Rp-Nucleoside Analog
|
|
WO2014099941A1
(en)
|
2012-12-19 |
2014-06-26 |
Idenix Pharmaceuticals, Inc. |
4'-fluoro nucleosides for the treatment of hcv
|
|
JP6284547B2
(ja)
|
2012-12-21 |
2018-02-28 |
アリオス バイオファーマ インク． |
置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体
|
|
KR20200060782A
(ko)
|
2013-01-31 |
2020-06-01 |
길리애드 파마셋 엘엘씨 |
두 항바이러스 화합물의 병용 제형물
|
|
WO2014121417A1
(en)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
|
WO2014121418A1
(en)
|
2013-02-07 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
|
|
WO2014137926A1
(en)
|
2013-03-04 |
2014-09-12 |
Idenix Pharmaceuticals, Inc. |
3'-deoxy nucleosides for the treatment of hcv
|
|
US9339541B2
(en)
|
2013-03-04 |
2016-05-17 |
Merck Sharp & Dohme Corp. |
Thiophosphate nucleosides for the treatment of HCV
|
|
WO2014160484A1
(en)
|
2013-03-13 |
2014-10-02 |
Idenix Pharmaceuticals, Inc. |
Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
|
|
RU2534613C2
(ru)
|
2013-03-22 |
2014-11-27 |
Александр Васильевич Иващенко |
Алкил 2-{ [(2r,3s,5r)-5-(4-амино-2-оксо-2н-пиримидин-1-ил)- -гидрокси-тетрагидро-фуран-2-илметокси]-фенокси-фосфориламино} -пропионаты, нуклеозидные ингибиторы рнк-полимеразы hcv ns5b, способы их получения и применения
|
|
WO2014165542A1
(en)
|
2013-04-01 |
2014-10-09 |
Idenix Pharmaceuticals, Inc. |
2',4'-fluoro nucleosides for the treatment of hcv
|
|
EP3004130B1
(en)
|
2013-06-05 |
2019-08-07 |
Idenix Pharmaceuticals LLC. |
1',4'-thio nucleosides for the treatment of hcv
|
|
EP3027636B1
(en)
|
2013-08-01 |
2022-01-05 |
Idenix Pharmaceuticals LLC |
D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
|
|
EP3650014B1
(en)
|
2013-08-27 |
2021-10-06 |
Gilead Pharmasset LLC |
Combination formulation of two antiviral compounds
|
|
WO2015042375A1
(en)
|
2013-09-20 |
2015-03-26 |
Idenix Pharmaceuticals, Inc. |
Hepatitis c virus inhibitors
|
|
WO2015061683A1
(en)
|
2013-10-25 |
2015-04-30 |
Idenix Pharmaceuticals, Inc. |
D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
|
|
EP3063272A2
(en)
|
2013-10-30 |
2016-09-07 |
Green Life Biotech, LLC |
Pathogenesis quantification systems and treatment methods for citrus greening blight
|
|
EP3063165A1
(en)
|
2013-11-01 |
2016-09-07 |
Idenix Pharmaceuticals LLC |
D-alanine phosphoramidate pronucleotides of 2'-methyl 2'-fluoro guanosine nucleoside compounds for the treatment of hcv
|
|
EP3074399A1
(en)
|
2013-11-27 |
2016-10-05 |
Idenix Pharmaceuticals LLC |
2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection
|
|
WO2015095419A1
(en)
|
2013-12-18 |
2015-06-25 |
Idenix Pharmaceuticals, Inc. |
4'-or nucleosides for the treatment of hcv
|
|
WO2015123352A1
(en)
|
2014-02-13 |
2015-08-20 |
Ligand Pharmaceuticals, Inc. |
Prodrug compounds and their uses
|
|
WO2015134560A1
(en)
|
2014-03-05 |
2015-09-11 |
Idenix Pharmaceuticals, Inc. |
Solid forms of a flaviviridae virus inhibitor compound and salts thereof
|
|
US20170135990A1
(en)
|
2014-03-05 |
2017-05-18 |
Idenix Pharmaceuticals Llc |
Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
|
|
EP3131914B1
(en)
|
2014-04-16 |
2023-05-10 |
Idenix Pharmaceuticals LLC |
3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
|
|
US9994600B2
(en)
|
2014-07-02 |
2018-06-12 |
Ligand Pharmaceuticals, Inc. |
Prodrug compounds and uses therof
|
|
MY190867A
(en)
|
2015-03-06 |
2022-05-13 |
Atea Pharmaceuticals Inc |
? -d-2'-deoxy-2'-?-fluoro-2'- ? -c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
|
|
US10202412B2
(en)
|
2016-07-08 |
2019-02-12 |
Atea Pharmaceuticals, Inc. |
β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
|
|
US10711029B2
(en)
|
2016-07-14 |
2020-07-14 |
Atea Pharmaceuticals, Inc. |
Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
|
|
PL3512863T3
(pl)
|
2016-09-07 |
2022-04-04 |
Atea Pharmaceuticals, Inc. |
2'-Podstawione-N6-podstawione nukleotydy purynowe do leczenia zakażeń wirusem RNA
|
|
US11234454B2
(en)
|
2016-12-15 |
2022-02-01 |
Société des Produits Nestlé S.A. |
Compositions and methods that modulate cholesterol in a companion animal
|
|
CN109328018A
(zh)
|
2016-12-15 |
2019-02-12 |
雀巢产品技术援助有限公司 |
调节伴侣动物体内的磷或酶的组合物和方法
|
|
IL295609B2
(en)
|
2017-02-01 |
2023-11-01 |
Atea Pharmaceuticals Inc |
Nucleotide hemisulfate salt for the treatment of hepatitis C virus
|
|
ES2892402T3
(es)
|
2017-08-01 |
2022-02-04 |
Gilead Sciences Inc |
Formas cristalinas de ((S)-((((2R,5R)-5-(6-amino-9H-purin-9-il)-4-fluoro-2,5-dihidrofuran-2-il)oxi)metil)(fenoxi)fosforil)-L-alaninato de etilo para tratar infecciones virales
|
|
AU2019207625A1
(en)
|
2018-01-09 |
2020-07-30 |
Ligand Pharmaceuticals, Inc. |
Acetal compounds and therapeutic uses thereof
|
|
CN112351799A
(zh)
|
2018-04-10 |
2021-02-09 |
阿堤亚制药公司 |
具有硬化的hcv感染患者的治疗
|
|
JP7496132B2
(ja)
*
|
2018-08-31 |
2024-06-06 |
国立大学法人 鹿児島大学 |
核酸アナログ及び抗ｂ型肝炎ウイルス剤
|
|
US20220099637A1
(en)
|
2018-12-04 |
2022-03-31 |
Bristol-Myers Squibb Company |
Methods of analysis using in-sample calibration curve by multiple isotopologue reaction monitoring
|
|
US10874687B1
(en)
|
2020-02-27 |
2020-12-29 |
Atea Pharmaceuticals, Inc. |
Highly active compounds against COVID-19
|
|
WO2022245814A1
(en)
*
|
2021-05-17 |
2022-11-24 |
Rome Therapeutics, Inc. |
Methods of treating medical conditions and inhibiting line1 reverse transcriptase using a substituted 4-fluoro-2,5-dihydrofuranyl phosphonic acid or related compound
|
|
BR112023026356A2
(pt)
|
2021-06-17 |
2024-03-05 |
Atea Pharmaceuticals Inc |
Método para tratar vírus da hepatite c ou uma condição resultante de uma infecção por hepatite c, combinação, uso da combinação, composição farmacêutica, e, kit para o tratamento de vírus da hepatite c
|